dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Gabriel Medina, Pablo |
dc.contributor.author | Ferrer Costa, Roser |
dc.contributor.author | Rodríguez Frias, Francisco |
dc.contributor.author | Rivera Esteban, Jesus Manuel |
dc.contributor.author | Pericàs Pulido, Juan Manuel |
dc.contributor.author | Ciudin Mihai, Andreea |
dc.contributor.author | Augustin Recio, Salvador |
dc.contributor.author | Martinez Selva, David |
dc.date.accessioned | 2022-09-08T08:35:55Z |
dc.date.available | 2022-09-08T08:35:55Z |
dc.date.issued | 2022-05 |
dc.identifier.citation | Gabriel-Medina P, Ferrer-Costa R, Rodriguez-Frias F, Ciudin A, Augustin S, Rivera-Esteban J, et al. Influence of Type 2 Diabetes in the Association of PNPLA3 rs738409 and TM6SF2 rs58542926 Polymorphisms in NASH Advanced Liver Fibrosis. Biomedicines. 2022 May;10(5):1015. |
dc.identifier.issn | 2227-9059 |
dc.identifier.uri | https://hdl.handle.net/11351/8066 |
dc.description | Advanced fibrosis; Nonalcoholic steatohepatitis; Type 2 diabetes |
dc.description.abstract | Nonalcoholic steatohepatitis (NASH) is a leading cause of cirrhosis in western countries. Insulin resistance (IR), type 2 diabetes (T2D), and the polymorphisms patatin-like phospholipase domain-containing 3 (PNPLA3) rs738409 and transmembrane 6 superfamily member 2 (TM6SF2) rs58542926 are independent risk factors of NASH. Nevertheless, little is known about the interaction between IR and T2D with these polymorphisms in the pathogenesis of NASH and the development of advanced fibrosis. Thus, our study aimed to investigate this relationship. This is a cross-sectional study including NASH patients diagnosed by liver biopsy, at the Vall d’Hebron University Hospital. A total of 140 patients were included (93 T2D, 47 non-T2D). T2D (OR = 4.67; 95%CI 2.13–10.20; p < 0.001), PNPLA3 rs738409 and TM6SF2 rs58542926 polymorphisms (OR = 3.94; 95%CI 1.63–9.54; p = 0.002) were independently related with advanced liver fibrosis. T2D increased the risk of advance fibrosis on top of the two polymorphisms (OR = 14.69; 95%CI 3.03–77.35; p = 0.001 for PNPLA3 rs738409 and OR = 11.45; 95%CI 3.16–41.55; p < 0.001 for TM6SF2 rs58542926). In non-T2D patients, the IR (HOMA-IR ≥ 5.2, OR = 14.33; 95%CI 2.14–18.66; p = 0.014) increased the risk of advanced fibrosis when the polymorphisms were present (OR = 19.04; 95%CI 1.71–650.84; p = 0.042). The T2D and IR status increase the risk of advanced fibrosis in patients with NASH carrying the PNPLA3 rs738409 and/or TM6SF2 rs58542926 polymorphisms, respectively. |
dc.language.iso | eng |
dc.publisher | MDPI |
dc.relation.ispartofseries | Biomedicines;10(5) |
dc.rights | Attribution 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ |
dc.source | Scientia |
dc.subject | Diabetis no-insulinodependent |
dc.subject | Polimorfisme genètic |
dc.subject | Esteatosi hepàtica - Aspectes genètics |
dc.subject.mesh | Polymorphism, Single Nucleotide |
dc.subject.mesh | Diabetes Mellitus, Type 2 |
dc.subject.mesh | Non-alcoholic Fatty Liver Disease |
dc.title | Influence of Type 2 Diabetes in the Association of PNPLA3 rs738409 and TM6SF2 rs58542926 Polymorphisms in NASH Advanced Liver Fibrosis |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.3390/biomedicines10051015 |
dc.subject.decs | polimorfismo de nucleótido único |
dc.subject.decs | diabetes mellitus tipo II |
dc.subject.decs | esteatosis hepática no alcohólica |
dc.relation.publishversion | https://doi.org/10.3390/biomedicines10051015 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Gabriel-Medina P] Servei de Bioquímica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Departament de Bioquímica i Biologia Molecular, Universitat Autònoma de Barcelona, Bellaterra, Spain. Grup de Recerca en Bioquímica Clínica, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. [Ferrer-Costa R] Servei de Bioquímica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Grup de Recerca en Bioquímica Clínica, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. [Rodriguez-Frias F] Servei de Bioquímica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Departament de Bioquímica i Biologia Molecular, Universitat Autònoma de Barcelona, Bellaterra, Spain. Grup de Recerca en Bioquímica Clínica, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), 28029 Madrid, Spain. [Ciudin A] Servei d’Endocrinologia i Nutrició, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Grup de Recerca en Diabetis i Metabolisme, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), 28029 Madrid, Spain. [Augustin S, Pericàs JM] Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), 28029 Madrid, Spain. Unitat Hepàtica, Servei de Medicina Interna, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. [Rivera-Esteban J] Departament de Bioquímica i Biologia Molecular, Universitat Autònoma de Barcelona, Bellaterra, Spain. Unitat Hepàtica, Servei de Medicina Interna, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. [Martinez Selva D] Grup de Recerca en Diabetis i Metabolisme, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), 28029 Madrid, Spain |
dc.identifier.pmid | 35625751 |
dc.identifier.wos | 000802501100001 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |